Compare TR & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TR | PBLS |
|---|---|---|
| Founded | 1896 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.4B |
| IPO Year | 1994 | 2026 |
| Metric | TR | PBLS |
|---|---|---|
| Price | $38.64 | $29.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $41.00 |
| AVG Volume (30 Days) | 161.9K | ★ 1.0M |
| Earning Date | 10-21-2026 | 11-24-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 12.30 | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $300.17 |
| P/E Ratio | $54.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.95 | $22.66 |
| 52 Week High | $45.06 | $42.49 |
| Indicator | TR | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 56.45 | 51.85 |
| Support Level | $36.80 | $26.42 |
| Resistance Level | $39.48 | $41.72 |
| Average True Range (ATR) | 1.10 | 2.17 |
| MACD | 0.31 | 0.59 |
| Stochastic Oscillator | 77.22 | 77.46 |
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.